Cutaneous apocrine adenocarcinoma

Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm

Kerry L. Hollowell, Steven Agle, Emmanuel E. Zervos, Timothy L. Fitzgerald

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background and Objectives Apocrine adenocarcinoma is a rare neoplasm. There is a paucity of data on demographics and survival with no clear consensus on management of at risk lymph nodes, therefore, we analyzed a large cohort of patients identified via a national tumor registry. Methods Patients ages 17-91 from 1973 to 2006 were identified in the SEER registry and excluded breast and non-cutaneous neoplasms. Data analyzed included basic demographics, survival, surgical therapy, and stage. Results A total of 186 patients with apocrine adenocarcinoma were identified. The median age was 67 years, 76% were white and there was an equal distribution of males and females. The most common site was trunk (53%) followed by head and neck (35%). Surgery was performed on most patients (96%), either excision (50%) or wide excision (30%). Lymph node metastases were present in 69% patients undergoing node surgery. Median overall survival was 51.5 months. Positive lymph node status (P=0.006) and metastatic disease (P

Original languageEnglish (US)
Pages (from-to)415-419
Number of pages5
JournalJournal of Surgical Oncology
Volume105
Issue number4
DOIs
StatePublished - Mar 15 2012
Externally publishedYes

Fingerprint

Epidemiology
Adenocarcinoma
Skin
Lymph Nodes
Neoplasms
Survival
Registries
Demography
Therapeutics
Risk Management
Neck
Head
Breast Neoplasms
Neoplasm Metastasis

Keywords

  • cutaneous neoplasm
  • seer registry
  • sentinel lymph node

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Cutaneous apocrine adenocarcinoma : Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm. / Hollowell, Kerry L.; Agle, Steven; Zervos, Emmanuel E.; Fitzgerald, Timothy L.

In: Journal of Surgical Oncology, Vol. 105, No. 4, 15.03.2012, p. 415-419.

Research output: Contribution to journalArticle

Hollowell, Kerry L. ; Agle, Steven ; Zervos, Emmanuel E. ; Fitzgerald, Timothy L. / Cutaneous apocrine adenocarcinoma : Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm. In: Journal of Surgical Oncology. 2012 ; Vol. 105, No. 4. pp. 415-419.
@article{1a6288b5b3ba4264895df7e672e3f7b4,
title = "Cutaneous apocrine adenocarcinoma: Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm",
abstract = "Background and Objectives Apocrine adenocarcinoma is a rare neoplasm. There is a paucity of data on demographics and survival with no clear consensus on management of at risk lymph nodes, therefore, we analyzed a large cohort of patients identified via a national tumor registry. Methods Patients ages 17-91 from 1973 to 2006 were identified in the SEER registry and excluded breast and non-cutaneous neoplasms. Data analyzed included basic demographics, survival, surgical therapy, and stage. Results A total of 186 patients with apocrine adenocarcinoma were identified. The median age was 67 years, 76{\%} were white and there was an equal distribution of males and females. The most common site was trunk (53{\%}) followed by head and neck (35{\%}). Surgery was performed on most patients (96{\%}), either excision (50{\%}) or wide excision (30{\%}). Lymph node metastases were present in 69{\%} patients undergoing node surgery. Median overall survival was 51.5 months. Positive lymph node status (P=0.006) and metastatic disease (P",
keywords = "cutaneous neoplasm, seer registry, sentinel lymph node",
author = "Hollowell, {Kerry L.} and Steven Agle and Zervos, {Emmanuel E.} and Fitzgerald, {Timothy L.}",
year = "2012",
month = "3",
day = "15",
doi = "10.1002/jso.22023",
language = "English (US)",
volume = "105",
pages = "415--419",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Cutaneous apocrine adenocarcinoma

T2 - Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm

AU - Hollowell, Kerry L.

AU - Agle, Steven

AU - Zervos, Emmanuel E.

AU - Fitzgerald, Timothy L.

PY - 2012/3/15

Y1 - 2012/3/15

N2 - Background and Objectives Apocrine adenocarcinoma is a rare neoplasm. There is a paucity of data on demographics and survival with no clear consensus on management of at risk lymph nodes, therefore, we analyzed a large cohort of patients identified via a national tumor registry. Methods Patients ages 17-91 from 1973 to 2006 were identified in the SEER registry and excluded breast and non-cutaneous neoplasms. Data analyzed included basic demographics, survival, surgical therapy, and stage. Results A total of 186 patients with apocrine adenocarcinoma were identified. The median age was 67 years, 76% were white and there was an equal distribution of males and females. The most common site was trunk (53%) followed by head and neck (35%). Surgery was performed on most patients (96%), either excision (50%) or wide excision (30%). Lymph node metastases were present in 69% patients undergoing node surgery. Median overall survival was 51.5 months. Positive lymph node status (P=0.006) and metastatic disease (P

AB - Background and Objectives Apocrine adenocarcinoma is a rare neoplasm. There is a paucity of data on demographics and survival with no clear consensus on management of at risk lymph nodes, therefore, we analyzed a large cohort of patients identified via a national tumor registry. Methods Patients ages 17-91 from 1973 to 2006 were identified in the SEER registry and excluded breast and non-cutaneous neoplasms. Data analyzed included basic demographics, survival, surgical therapy, and stage. Results A total of 186 patients with apocrine adenocarcinoma were identified. The median age was 67 years, 76% were white and there was an equal distribution of males and females. The most common site was trunk (53%) followed by head and neck (35%). Surgery was performed on most patients (96%), either excision (50%) or wide excision (30%). Lymph node metastases were present in 69% patients undergoing node surgery. Median overall survival was 51.5 months. Positive lymph node status (P=0.006) and metastatic disease (P

KW - cutaneous neoplasm

KW - seer registry

KW - sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=84857037301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857037301&partnerID=8YFLogxK

U2 - 10.1002/jso.22023

DO - 10.1002/jso.22023

M3 - Article

VL - 105

SP - 415

EP - 419

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -